Currently, only a few molecular markers have been implemented for the management of CRC although these have mainly been for therapy stratification such as testing for activating KRAS, NRAS and BRAF gene mutations as exclusion criteria for the use of EGFR-targeted therapies in metastatic CRC (mCRC) [2]. The gene discussed is KRAS; the disease is colorectal carcinoma.